Work

Abstract C31: Phase 1 study of AV-412, a novel irreversible EGFR inhibitor, administered daily in patients with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-c31

Authors: Pankaj Bhargava, Dan Laheru, Carmen Pupareli, Maximiliano Van Kooten, Justina L. Martinez, Monica Varela, Monette M. Cotreau, Marc Credi, Mohammed Al-Adhami, Debra L. Wood, Manuel Hidalgo

Institutions: AVEO Oncology (United States), Sidney Kimmel Comprehensive Cancer Center, Instituto Alexander Fleming, Hospital Universitario Austral, Vermont Technical College, Spanish National Cancer Research Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2078547908

Cites:

Cited by: 1

Related to: 10